Vitamin B12 and Folate: who runs low and How Labs Guide It

Adults most likely to run low on B12 or folate include older adults, vegans, people on metformin or long-term acid suppressants, and those with celiac or bariatric surgery. Symptoms can include fatigue, neuropathy, glossitis, and cognitive fog. Serum B12, folate, and often MMA or homocysteine help clarify whether supplementing is warranted and in what form.

Vitamin B12 (cobalamin) and folate (vitamin B9) are the two water-soluble B vitamins most likely to show up as a real clinical problem on a routine panel. They sit next to each other in the methylation pathway, their deficiencies look nearly identical on a blood smear, and treating one while missing the other can actually make the other worse. That is why the lab workup matters more than the supplement aisle.

This article walks through who tends to run low, what symptoms to take seriously, and how the specific markers — serum B12, folate, methylmalonic acid (MMA), and homocysteine — guide what to do next.

Who actually runs low — the real risk list

Population estimates vary, but clinically meaningful B12 deficiency affects roughly 6% of adults under 60 and climbs with age; folate deficiency is less common in countries with fortified grain supplies but still shows up in specific groups.

The people most likely to run low:

• Adults over 60, due to declining gastric acid and intrinsic factor production
• Vegans and strict vegetarians, because B12 is essentially absent from plant foods
• People on long-term metformin — the Diabetes Prevention Program Outcomes Study found measurably lower B12 with chronic use
• People on long-term PPIs or H2 blockers, which blunt the acid needed to free B12 from food protein
• Celiac disease, Crohn's, or prior bariatric/gastric surgery, which impair absorption directly
• Pernicious anemia, an autoimmune loss of intrinsic factor
• Pregnancy and heavy alcohol use for folate specifically
• Patients on methotrexate, sulfasalazine, or certain antiepileptics, which interfere with folate

If none of these apply and the diet is reasonable, pre-emptive B-vitamin supplementation rarely moves the needle. If several apply, testing before supplementing is the honest move — because supplementing blind can mask the diagnosis.

The symptoms — what deficiency actually feels like

Early deficiency is quiet. By the time it is loud, it has usually been building for months to years.

Common early signs:

• Fatigue that does not match sleep or workload
• Glossitis (a smooth, sore, beefy-red tongue)
• Pallor or shortness of breath on exertion
• Mild cognitive fog, poor concentration, low mood

More advanced B12-specific signs — these are the ones not to shrug off:

• Paresthesias (tingling, pins-and-needles) in hands and feet
• Loss of vibration or position sense, unsteady gait
• Memory changes, in some cases mimicking early dementia

The neurologic symptoms are the critical ones because they can become permanent if deficiency is prolonged. Folate deficiency produces the same megaloblastic anemia but does not typically produce the neuropathy — which is one reason distinguishing the two matters.

If B12 is low and only folate is replaced, the anemia can correct while the neurologic damage silently progresses.

The labs that matter — in plain English

A CBC often hints at the problem before the vitamin levels are drawn. Classic findings are a high MCV (macrocytosis, usually >100 fL) and hypersegmented neutrophils. But the MCV can be normal in up to a quarter of deficient patients, especially if iron deficiency is masking it, so you cannot rule out deficiency on the CBC alone.

The markers worth having when B12 or folate deficiency is on the table:

• Serum B12 (cobalamin) — straightforward, but the "normal" range is wide and the lower end (roughly 200–300 pg/mL in most US labs) is a grey zone where symptomatic people can still be deficient.
• Serum folate — reflects recent intake and can look normal shortly after a single folate-rich meal; red cell folate is a steadier measure if available.
• Methylmalonic acid (MMA) — elevated in true B12 deficiency and more specific than serum B12 when the serum level is borderline. Per the British Society for Haematology guideline, MMA is the preferred confirmatory test in the grey zone.
• Homocysteine — elevated in both B12 and folate deficiency, so useful but not specific.
• Intrinsic factor antibodies — order when pernicious anemia is suspected.

The key distinctionA borderline serum B12 with elevated MMA is functional B12 deficiency and deserves treatment, even if the B12 number looks "in range."

How results guide supplementing — tuned to your numbers

Once the pattern is clear, the form and route of replacement follow from it. This is where lab-blind supplementing goes wrong: the same "B-complex" bottle treats a mild dietary gap and a severe absorption problem identically, and only one of those situations will actually respond.

If B12 is clearly low with neurologic symptoms or confirmed pernicious anemia, standard practice per the BSH guideline is intramuscular hydroxocobalamin on a loading schedule followed by maintenance injections. Oral high-dose cobalamin can be effective in some non-pernicious cases, but the decision belongs with a clinician who has seen the labs and the history.

If B12 is borderline with elevated MMA and no neurologic signs, oral or sublingual cobalamin is often reasonable, with a repeat level in 2–3 months to confirm response.

If folate is low, oral folic acid or 5-MTHF (methylfolate) replaces it reliably — but B12 must be checked and corrected first or in parallel. Giving folate alone to a B12-deficient patient can resolve the anemia while allowing the neuropathy to worsen.

If both are normal and symptoms persist, the answer is not more B vitamins. Thyroid, iron studies, sleep, and depression screening typically come next.

A note on methylfolate and MTHFR

MTHFR gene variants are common and have been heavily marketed as a reason to take methylfolate instead of folic acid. For most people with adequate folate intake, the clinical difference is modest. Where methylfolate makes more sense is in patients with documented low folate who are not responding well to folic acid, or when a clinician is working through a specific pregnancy or psychiatric indication.

When to retest

After starting replacement, reticulocytes rise within a week and hemoglobin typically normalizes over 6–8 weeks. Recheck B12, folate, and MMA (if it was the marker that confirmed deficiency) at roughly 3 months. Neurologic recovery lags behind the blood counts and may take months — another reason not to delay treatment once the diagnosis is in.

For patients on metformin, PPIs, or with a malabsorption diagnosis, annual B12 monitoring is reasonable because the underlying driver does not go away.

The bottom line

B12 and folate deficiencies are common enough to screen for in the right patient, specific enough to confirm with the right follow-up labs, and consequential enough — particularly the neurologic side of B12 — that guessing is not a good strategy. The useful workflow is: identify risk, test the right markers, interpret in context, then supplement with the form and route the results actually call for.

If you want the markers above run and interpreted alongside your symptoms, that is the kind of workup worth having before committing to any long-term supplement regimen.

References

1. Stabler SP. Vitamin B12 Deficiency. New England Journal of Medicine. 2013;368:149-160. Source
2. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology. 2014;166(4):496-513. Source
3. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754-1761. Source
4. Allen LH. How common is vitamin B-12 deficiency? American Journal of Clinical Nutrition. 2009;89(2):693S-696S. Source
5. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nature Reviews Disease Primers. 2017;3:17040. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.